R. Spiera

发表

A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis.

E. Petricoin, B. Hitt, L. Liotta, 2005, Arthritis and rheumatism.

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2013, The New England journal of medicine.

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

P. Merkel, J. Stone, John C. Davis, 2005, Arthritis and rheumatism.

ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis.

Augustine S. Lee, P. Merkel, J. Stone, 2007, The American journal of medicine.

Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis

D. Schroeder, P. Merkel, J. Stone, 2007, Annals of Internal Medicine.

Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2016, Arthritis & rheumatology.

2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative

K. Barraclough, E. Matteson, P. Perel, 2015, Arthritis & rheumatology.

Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis

J. Gordon, R. Spiera, 2010, Current opinion in rheumatology.

The association of serum calprotectin ( S 100 A 8 / S 100 A 9 ) levels with disease relapses in PR 3-ANCA-associated vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2016 .

Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial

P. Merkel, J. Stone, C. Kallenberg, 2011 .

Response to: ‘Correspondence on ‘Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement’’ by Manetti

J. Gordon, D. Orange, R. Spiera, 2020, Annals of the Rheumatic Diseases.

Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2016, Analytical chemistry.

Imatinib and the Treatment of Fibrosis: Recent Trials and Tribulations

J. Gordon, R. Spiera, 2011, Current rheumatology reports.

Cyclophosphamide Responsive Interstitial Lung Disease in “Overlap Syndrome”

A. Bass, R. Spiera, K. Kirou, 2011, HSS Journal.

Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis

J. Krischer, P. Merkel, J. Stone, 2012, PloS one.

Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program

Richard S. Henry, M. Suarez‐Almazor, B. Levis, 2022, Pilot and Feasibility Studies.

Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

Tammara A. Wood, M. Whitfield, J. Gordon, 2015, Arthritis Research & Therapy.

2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative

K. Barraclough, E. Matteson, P. Perel, 2015, Annals of the rheumatic diseases.

Domains of health-related quality of life important to patients with giant cell arteritis.

H. Rubin, P. Merkel, J. Stone, 2003, Arthritis and rheumatism.

Therapy for giant cell arteritis: can we do better?

H. Spiera, R. Spiera, 2006, Arthritis and rheumatism.

Inhibition of β-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82.

Julio C. Mantero, R. Simms, J. Gordon, 2017, The Journal of investigative dermatology.

A RANDOMIZED , DOUBLE-BLIND TRIAL OF ABATACEPT ( CTLA 4-IG ) FOR THE TREATMENT OF TAKAYASU ’ S ARTERITIS

Larry, Nader, Khalidi, 2017 .

A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Takayasu Arteritis

J. Krischer, P. Merkel, M. Weisman, 2017, Arthritis & rheumatology.

A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis

J. Krischer, P. Merkel, M. Weisman, 2017, Arthritis & rheumatology.

Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial

J. Stone, M. Aringer, D. Blockmans, 2021 .

Arterial lesions in giant cell arteritis: A longitudinal study.

P. Merkel, L. Moreland, P. Monach, 2019, Seminars in arthritis and rheumatism.

Trial of Tocilizumab in Giant‐Cell Arteritis

J. Stone, M. Aringer, G. Schett, 2017, The New England journal of medicine.

Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis.

N. Narula, R. Spiera, A. Pernis, 2015, Rheumatology.

Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy

M. Richmond, M. Kupersmith, H. Spiera, 1999, The British journal of ophthalmology.

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

J. Stone, J. Best, R. Spiera, 2021, Arthritis Research & Therapy.

Rare Manifestation of Granulomatosis With Polyangiitis

A. Bass, D. Tarnow, R. Spiera, 2013 .

Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.

D. Schroeder, P. Merkel, J. Stone, 2011, Arthritis and rheumatism.

Current therapies for ANCA-associated vasculitis.

R. Spiera, Lindsay Lally, L. Lally, 2015, Annual review of medicine.

Biomarkers in ANCA-Associated Vasculitis

R. Spiera, Lindsay Lally, L. Lally, 2013, Current Rheumatology Reports.

Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis.

D. Schroeder, P. Merkel, J. Stone, 2009, Clinical and experimental rheumatology.

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.

P. Merkel, J. Stone, John C. Davis, 2006, Arthritis and rheumatism.

A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).

M. Peterson, M. Kupersmith, H. Spiera, 2001, Clinical and experimental rheumatology.

Churg–Strauss Syndrome with Eosinophilic Myocarditis

J. Weinsaft, Y. Endo, A. Bass, 2012, HSS Journal ®.

IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis

P. Merkel, J. Stone, John C. Davis, 2011, Proceedings of the National Academy of Sciences.

Clinical Manifestations and Long‐Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America

P. Merkel, L. Moreland, S. Chung, 2021, ACR open rheumatology.

Thromboembolism—Another Threat to the Polymorbid Patient with Vasculitis?: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142: 620–626, 2005

P. Merkel, J. Stone, John C. Davis, 2005 .

Rituximab for the Treatment of Relapses in ANCA-associated Vasculitis

P. Merkel, J. Stone, L. Viviano, 2014 .

Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, L. Viviano, 2014, Arthritis & rheumatology.

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

P. Merkel, M. Weisman, M. Nodale, 2020, Annals of the Rheumatic Diseases.

Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Is There Still a Role for Cyclophosphamide?

R. Spiera, S. Sattui, 2019, Rheumatic diseases clinics of North America.

Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2019, Arthritis & rheumatology.

Outcomes of Nonsevere Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated With Glucocorticoids

P. Merkel, J. Stone, C. Kallenberg, 2015, Arthritis & rheumatology.

Current landscape of antineutrophil cytoplasmic antibody-associated vasculitis: classification, diagnosis, and treatment.

R. Spiera, Lindsay Lally, L. Lally, 2015, Rheumatic diseases clinics of North America.

Practice patterns of ANCA-associated vasculitis: exploring differences among subspecialties at a single academic medical centre.

R. Spiera, L. Forbess, K. Griffin, 2014, Clinical and experimental rheumatology.

Effectiveness of Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis (Wegener's)

R. Spiera, R. Lebovics, Lindsay Lally, 2014, Arthritis care & research.

Vasculitis and Pregnancy

R. Spiera, Lindsay Lally, L. Lally, 2014 .

Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2019, Arthritis & rheumatology.

Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

D. Schroeder, P. Merkel, J. Stone, 2018 .

Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

D. Schroeder, P. Merkel, J. Stone, 2018, Arthritis & rheumatology.

Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive and ANCA‐Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets

P. Merkel, J. Stone, C. Kallenberg, 2016, Arthritis & rheumatology.

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2013, Arthritis and rheumatism.

Activation of a Latent Epitope Causing Differential Binding of Anti-Neutrophil Cytoplasmic Antibodies to Proteinase 3

P. Merkel, J. Stone, C. Kallenberg, 2019, bioRxiv.

Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis

D. Schroeder, P. Merkel, J. Stone, 2018, Rheumatology.

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis

P. Merkel, J. Stone, E. S. St. Clair, 2017, Clinical and experimental immunology.

Relationship Between Markers of Platelet Activation and Inflammation with Disease Activity in Wegener’s Granulomatosis

P. Merkel, J. Stone, J. Freedman, 2011, The Journal of Rheumatology.

Rho Kinase Expression in Giant Cell Arteritis: Validating Phosphorylated Ezrin/Radixin/Moesin Intensity Score to Increase Sensitivity of Temporal Artery Biopsy

N. Narula, D. Pisapia, R. Luqmani, 2022, The Journal of Rheumatology.

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab

J. Stone, M. Aringer, G. Schett, 2019, Arthritis & rheumatology.

279 – Polymyalgia Rheumatica and Temporal Arteritis

R. Spiera, S. Paget, 2012 .

Methotrexate in giant-cell arteritis.

H. Spiera, R. Spiera, S. Paget, 2001, Annals of internal medicine.

Inflammatory disease in older adults. Cranial arteritis.

H. Spiera, R. Spiera, 2004, Geriatrics.

Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study

P. Merkel, J. Stone, John C. Davis, 2005, Annals of Internal Medicine.

Ticlopidine-induced lupus: a report of 4 cases.

A. J. Werner, H. Spiera, R. Spiera, 2002, Archives of internal medicine.

Submaximal Heart and Pulmonary Evaluation: A Novel Noninvasive Test to Identify Pulmonary Hypertension in Patients With Systemic Sclerosis

L. Mandl, J. Gordon, R. Spiera, 2013, Arthritis care & research.

Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA‐Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2021, ACR open rheumatology.

Chronic activation of pDCs in autoimmunity is linked to dysregulated ER stress and metabolic responses

J. Gordon, M. Crow, R. L. Wiseman, 2022, The Journal of experimental medicine.

Herpes zoster in immunocompromised patients: incidence, timing, and risk factors.

P. Merkel, J. Stone, John C. Davis, 2005, The American journal of medicine.

Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies

J. Gordon, R. Spiera, 2011, International journal of rheumatology.

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

J. Gordon, S. Lyman, M. Crow, 2011, Annals of the rheumatic diseases.

Adipose‐Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial

Richard W. Martin, M. Mayes, D. Furst, 2022, Arthritis & Rheumatology (Hoboken, N.j.).

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

M. Mayes, P. Merkel, D. Furst, 2008, Arthritis and rheumatism.

Alpha 1 -Antitrypsin Deficiency–Related Alleles Z and S and the Risk of Wegener’s Granulomatosis

P. Merkel, J. Stone, J. Edberg, 2011 .

Disease Activity, ANCA-Type, and Lipid Levels in ANCA-Associated Vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2019, Arthritis & rheumatology.

Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice.

R. Spiera, Lindsay Lally, L. Lally, 2018, Best practice & research. Clinical rheumatology.

Less Common Arthropathies

R. Spiera, 2008 .

Mental Health Care Use and Associated Factors in Systemic Sclerosis: A Scleroderma Patient‐Centered Intervention Network Cohort Study

B. Thombs, C. Mancuso, J. Gordon, 2022, ACR open rheumatology.

Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's)

S. Chow, P. Merkel, J. Stone, 2011, Arthritis care & research.

Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission

P. Merkel, J. Stone, E. S. St. Clair, 2022, Annals of the Rheumatic Diseases.

Physical or Occupational Therapy Use in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study

B. Thombs, C. Mancuso, J. Gordon, 2019, The Journal of Rheumatology.

Musculoskeletal Involvement in SSc Is Associated with Worse Scores on Short Form-36 and Scleroderma Health Assessment Questionnaire and Lower Tumor Necrosis Factor-α Gene Expression in Peripheral Blood Mononuclear Cells

J. Gordon, R. Spiera, F. Barrat, 2016, HSS Journal ®.

Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis

J. D. de Vries-Bouwstra, M. Hudson, M. Baron, 2021, Arthritis care & research.

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases

D. Jannat-Khah, R. Spiera, Sarah Jinich, 2021, Annals of the Rheumatic Diseases.

Silicone gel filled breast implants and connective tissue disease: an overview.

H. Spiera, R. Spiera, A. Gibofsky, 1994, The Journal of rheumatology.

Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up

M. Mayes, M. Baron, R. Simms, 2017 .

Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations.

P. Merkel, J. Stone, John C. Davis, 2007, The Journal of rheumatology.

The Recurrence of Digital Ulcers in Patients with Systemic Sclerosis after Discontinuation of Oral Treprostinil

Ami A. Shah, S. Peng, J. Cleveland, 2016, The Journal of Rheumatology.

OP0126 A phase 2 study of safety and efficacy of anabasum (JBT-101) in systemic sclerosis

M. Mayes, D. Furst, R. Simms, 2017 .

Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type

P. Merkel, J. Stone, Hyon K. Choi, 2015, Annals of the rheumatic diseases.

Newer therapeutic approaches to the vasculitides: biologic agents.

R. Spiera, J. Samuels, 2006, Rheumatic diseases clinics of North America.

B-cell-targeted therapy in systemic vasculitis

R. Spiera, Lindsay Lally, L. Lally, 2016, Current opinion in rheumatology.

Randomized controlled trial of an internet-based self-guided hand exercise program to improve hand function in people with systemic sclerosis: the Scleroderma Patient-centered Intervention Network Hand Exercise Program (SPIN-HAND) trial

Richard S. Henry, M. Suarez‐Almazor, B. Levis, 2022, Trials.

Esophageal involvement in Wegener's granulomatosis.

M. Bains, R. Spiera, D. Filippa, 1994, Arthritis and rheumatism.

Extramuscular manifestations in idiopathic inflammatory myopathies.

R. Spiera, L. Kagen, 1998, Current opinion in rheumatology.

Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial

S. Humphries, A. Wells, C. Denton, 2022, Rheumatology.

The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial

Richard S. Henry, M. Suarez‐Almazor, B. Levis, 2021, Trials.

Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients

Richard S. Henry, M. Suarez‐Almazor, D. Rice, 2020, Journal of Psychosomatic Research.

SAT0284 CD123+ PLASMACYTOID DENDRITIC CELLS (PDCS) FROM SYSTEMIC SCLEROSISPATIENTS ARE SUSCEPTIBLE TO THE CYTOTOXIC ACTIVITY OF TAGRAXOFUSP, A CD123-TARGETED THERAPY

J. Gordon, C. Brooks, R. Spiera, 2019, Saturday, 15 June 2019.

Belimumab for the Treatment of Early Diffuse Systemic Sclerosis

Tammara A. Wood, Jennifer M. Franks, M. Whitfield, 2018, Arthritis & rheumatology.

Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8

J. Gordon, C. Tripodo, M. Crow, 2018, Science Translational Medicine.

The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts

B. Thombs, M. Mayes, M. Hudson, 2018, Rheumatology.

Systemic sclerosis, myositis and related syndromes – etiology, pathogenesis and animal models

J. Gordon, C. Brooks, R. Spiera, 2022 .

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2010, The New England journal of medicine.

Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.

J. Krischer, P. Merkel, J. Stone, 2011, Arthritis and rheumatism.

A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis

P. Merkel, J. Stone, John C. Davis, 2011, Arthritis care & research.

Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3

D. Schroeder, P. Merkel, J. Stone, 2016, Arthritis & rheumatology.

A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.

P. Gregersen, C. Wijmenga, J. Barrett, 2015, American journal of human genetics.

Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis

J. Krischer, P. Merkel, J. Stone, 2011, Annals of the rheumatic diseases.

Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.

P. Merkel, J. Jover, B. Fernández-Gutiérrez, 2007, Arthritis and rheumatism.

Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis.

J. Gordon, R. Lafyatis, J. Browning, 2016, The Journal of clinical investigation.

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis

Naoto Hirano, Christopher I. Amos, Xuemei Ji, 2017, Arthritis & rheumatology.

Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis

P. Merkel, J. Stone, C. Kallenberg, 2020, JCI insight.

Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity.

Alex Kuo, Purvesh Khatri, Shane Lofgren, 2016, JCI insight.

P. Merkel, J. Stone, C. Kallenberg, 2015, Arthritis & rheumatology.

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.

M. Whitfield, L. Rice, Jessica Ziemek, 2015, The Journal of clinical investigation.

Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2015, Arthritis & rheumatology.

Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis.

K. Siminovitch, P. Merkel, J. Stone, 2012, Arthritis and rheumatism.

Inflammatory diseases in older adults: polymyalgia rheumatica.

H. Spiera, R. Spiera, 2004, Geriatrics.

Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis.

P. Merkel, J. Stone, K. Fontaine, 2008, Arthritis and rheumatism.

A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).

P. Merkel, J. Stone, Y. Min, 2001, Arthritis and rheumatism.

Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis

Devin K. Schweppe, Jaclyn N. Taroni, P. Anderson, 2016, Arthritis Research & Therapy.

The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.

P. Merkel, J. Stone, C. Kallenberg, 2018, Clinical journal of the American Society of Nephrology : CJASN.

Pulmonary vasculitis.

R. Spiera, Lindsay Lally, L. Lally, 2015, Rheumatic diseases clinics of North America.

Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis.

Stephan Ripke, Delnaz Roshandel, Soumya Raychaudhuri, 2013, Arthritis and rheumatism.

Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment

J. Gordon, L. Chung, P. Utz, 2017, The Journal of Rheumatology.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.

P. Merkel, J. Stone, C. Kallenberg, 2015, Journal of the American Society of Nephrology : JASN.

Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis : Which Subsets Are At Greatest Risk for Flare?

P. Merkel, J. Stone, C. Kallenberg, 2011 .

Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study.

P. Merkel, J. Stone, John C. Davis, 2005, Annals of internal medicine.

Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

P. Merkel, Javier Martín, M. González-Gay, 2017, Scientific Reports.

Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

B. Rovin, P. Merkel, T. Schall, 2020, ACR open rheumatology.

The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event.

P. Merkel, J. Stone, J. Loscalzo, 2007, The Journal of rheumatology.

Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

M. Konig, P. Merkel, J. Stone, 2022, Arthritis & rheumatology.

AB0626 Prevalence of Frailty in an Internet-Based Cohort with a Self-Reported Diagnosis of Vasculitis – The VascStrong Study

P. Merkel, R. Spiera, S. Sattui, 2022, Annals of the Rheumatic Diseases.

The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.

D. Schroeder, P. Merkel, J. Stone, 2019, Journal of autoimmunity.

Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis

P. Merkel, J. Stone, C. Kallenberg, 2017, American Journal of Nephrology.

Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis.

P. Merkel, J. Stone, John C. Davis, 2008, Arthritis and rheumatism.

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis

Tammara A. Wood, M. Mayes, D. Furst, 2020, Arthritis & rheumatology.

A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.

M. Baron, D. Furst, C. Denton, 2021, Clinical and experimental rheumatology.

B Cell Reconstitution Is Strongly Associated With COVID‐19 Vaccine Responsiveness in Rheumatic Disease Patients Who Received Treatment With Rituximab

D. Jannat-Khah, R. Spiera, Sarah Jinich, 2021, Arthritis & rheumatology.

Assessment of health‐related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's)

P. Merkel, J. Stone, M. Boers, 2012, Arthritis care & research.

B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab

D. Jannat-Khah, R. Spiera, Deanna Jannat-Khah, 2022, The Journal of Rheumatology.

Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA‐Associated Vasculitis

C. Kallenberg, Hyon K. Choi, P. Monach, 2016 .

LB0006 SARILUMAB IN PATIENTS WITH RELAPSING POLYMYALGIA RHEUMATICA: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL (SAPHYR)

F. Buttgereit, R. Spiera, A. Rubbert-Roth, 2022, Annals of the Rheumatic Diseases.

New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension

J. Stone, M. Aringer, D. Blockmans, 2021, Rheumatology.

Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial.

J. Stone, R. Spiera, M. Bao, 2021, Seminars in arthritis and rheumatism.

THU0329 SAFETY, TARGET ENGAGEMENT, AND INITIAL EFFICACY OF AVID200, A FIRST-IN-CLASS POTENT AND ISOFORM-SELECTIVE INHIBITOR OF TGF-BETA 1 AND 3, IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC): A PHASE 1 DOSE ESCALATION STUDY

A. Papazoglou, R. Domsic, R. Lafyatis, 2020 .

OP0325 SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS (DCSSC)

M. Mayes, D. Furst, R. Simms, 2019, Oral Presentations.

OP0006 Safety and efficacy of lenabasum (JBT-101) in diffuse cutaneous systemic sclerosis subjects treated for one year in an open-label extension of trial jbt101-ssc-001

M. Mayes, J. Gordon, L. Hummers, 2018, WEDNESDAY, 13 JUNE 2018.

Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2017, Arthritis care & research.

OP0171 PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)

D. Furst, J. Gordon, C. Denton, 2021 .

Brief Report: A Prospective Open‐Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica

R. Spiera, L. Forbess, Lindsay Lally, 2016, Arthritis & rheumatology.

Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study.

Richard S. Henry, M. Suarez‐Almazor, B. Levis, 2021, The Lancet. Rheumatology.

Comparison of change in end tidal carbon dioxide after three minutes of step exercise between systemic sclerosis patients with and without pulmonary hypertension

L. Mandl, J. Gordon, R. Spiera, 2017, Rheumatology.

Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement

Tammara A. Wood, Jennifer M. Franks, P. Agius, 2020, Annals of the Rheumatic Diseases.

Integration of capillary microscopy and dermoscopy into the rheumatology fellow curriculum.

J. Gordon, M. Cutolo, R. Spiera, 2017, Clinical and experimental rheumatology.

A Longitudinal Biomarker for the Extent of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis

M. Whitfield, L. Rice, Giuseppina Stifano, 2015, Arthritis & rheumatology.

A Genomic Meta-Analysis of Clinical Variables and Their Association with Intrinsic Molecular Subsets in Systemic Sclerosis.

Tammara A. Wood, Jennifer M. Franks, M. Whitfield, 2022, Rheumatology.

Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.

Julio C. Mantero, Giuseppina Stifano, Jessica Ziemek, 2018, Clinical and experimental rheumatology.

The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

B. Rovin, P. Merkel, J. Stone, 2016, Arthritis & rheumatology.

Activation of a Latent Epitope Causing Differential Binding of Anti-Neutrophil Cytoplasmic Antibodies to Proteinase 3

P. Merkel, J. Stone, C. Kallenberg, 2022, bioRxiv.

Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis

D. Schroeder, P. Merkel, J. Stone, 2020, Frontiers in Immunology.

Alpha₁-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis.

P. Merkel, J. Stone, J. Edberg, 2010, Arthritis and rheumatism.

SAT0012 DETECTION OF CIRCULATING PR3-SPECIFIC B CELLS IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS

P. Merkel, J. Stone, J. Pers, 2019, SATURDAY, 15 JUNE 2019.

Richard S. Henry, M. Suarez‐Almazor, D. Rice, 2020, Journal of psychosomatic research.

Scleroderma in women with silicone breast implants: comment on the article by Sánchez-Guerrero et al.

H. Spiera, R. Spiera, A. Gibofsky, 1995, Arthritis and rheumatism.

Provisional classification [corrected] criteria for polymyalgia rheumatica: moving beyond clinical intuition?

R. Westhovens, R. Spiera, 2012, Arthritis and rheumatism.

OP0091 A Retrospective Look at the Recurrence of Digital Ulcers in Patients with Scleroderma after Discontinuation of Oral Treprostinil

R. Spiera, T. Frech, E. Schiopu, 2014 .

Vision loss in giant cell arteritis patients treated with alternate-day corticosteroids: comment on the article by Hoffman et al.

M. Kupersmith, H. Spiera, R. Spiera, 2003, Arthritis and rheumatism.

Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis

P. Merkel, J. Stone, C. Kallenberg, 2021, JCI insight.

Design of the Tocilizumab in Giant Cell Arteritis Trial

J. Stone, J. Zwerina, G. Schett, 2013, International journal of rheumatology.

Brief Report: The Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener's)

P. Merkel, J. Stone, John C. Davis, 2014, Arthritis & rheumatology.

Corrigendum: Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

P. Merkel, Javier Martín, M. González-Gay, 2017, Scientific Reports.

Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial

J. Stone, M. Aringer, D. Blockmans, 2019 .

Low prevalence of coeliac disease in patients with systemic sclerosis: a cross-sectional study of a registry cohort.

J. Gordon, S. Lyman, R. Spiera, 2013, Rheumatology.

053. CLINICAL UTILITY OF SERIAL MEASUREMENTS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES TARGETING PROTEINASE 3 IN ANCA-ASSOCIATED VASCULITIS

D. Schroeder, P. Merkel, J. Stone, 2019, Rheumatology.

Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

M. Mayes, J. D. de Vries-Bouwstra, E. Lee, 2023, Arthritis & rheumatology.

Richard S. Henry, M. Suarez‐Almazor, B. Levis, 2021, Trials.

Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism

P. Merkel, C. Kallenberg, M. Prunotto, 2023, RMD Open.

2012 Annual Report

S. Seo, H. McArthur, J. Rosenberg, 2012 .

Adipose-Derived Regenerative Cell Transplantation in Systemic Sclerosis: Scleroderma Treatment with Celution Processed Adipose Derived Regenerative Cells- a Randomized Clinical Trial.

Richard W. Martin, M. Mayes, D. Furst, 2022, Arthritis & rheumatology.

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.

J. Gordon, S. Lyman, M. Crow, 2014, Clinical and experimental rheumatology.

Patterns of patient-reported symptoms and association with sociodemographic and systemic sclerosis disease characteristics: a scleroderma Patient-centered Intervention Network (SPIN) Cohort cross-sectional study

Richard S. Henry, M. Suarez‐Almazor, B. Levis, 2023, EClinicalMedicine.

Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis.

K. Siminovitch, S. Raychaudhuri, C. Amos, 2013, Arthritis and rheumatism.

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.

M. Whitfield, L. Rice, Jessica Ziemek, 2015, The Journal of clinical investigation.

A3.32 Efficacy of rituximab for the otolaryngologic manifestations of granulomatosis with polyangiitis

R. Spiera, R. Lebovics, Wei-Ti Huang, 2014 .

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

C. Kallenberg, L. Viviano, B. Fessler, 2013, The New England journal of medicine.

Excitatory amino acid antagonists depress acoustic startle after infusion into the ventral nucleus of the lateral lemniscus or paralemniscal zone

Michael Davis, R. Spiera, 1988, Brain Research.

A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.

C. Wijmenga, J. Barrett, B. Lie, 2017, American journal of human genetics.

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

R. Spiera, S. Unizony, M. Nivens, 2023, Arthritis Research & Therapy.

Disease Activity, ANCA-Type, and Lipid Levels in ANCA-Associated Vasculitis

Hyon K. Choi, K. Liao, P. Monach, 2020 .

Provisional diagnostic criteria for polymyalgia rheumatica: moving beyond clinical intuition?

R. Westhovens, R. Spiera, 2012, Annals of the rheumatic diseases.

2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative

K. Barraclough, E. Matteson, P. Perel, 2015, Annals of the rheumatic diseases.

2015 Recommendations for the Management of Polymyalgia Rheumatica

C. Pease, R. Spiera, J. Hollywood, 2015 .

Current therapies for ANCA-associated vasculitis.

R. Spiera, L. Lally, 2015, Annual review of medicine.

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

M. Nodale, L. Moreland, C. Pusey, 2023, Annals of the Rheumatic Diseases.

The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.

F. Pieruzzi, B. Rovin, V. Strand, 2023, The Lancet. Rheumatology.

Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.

G. Yancopoulos, R. Spiera, R. Bhore, 2023, The New England journal of medicine.

Therapeutic myeloperoxidase inhibition attenuates neutrophil activation, ANCA-mediated endothelial damage and crescentic glomerulonephritis

P. Monach, E. Michaëlsson, R. Unwin, 2019 .

Damage in ANCA-associated vasculitis: Preliminary evidence for the ANCA-associated vasculitis index of damage (AVID).

J. Stone, C. Kallenberg, E. Clair, 2006 .

Physical or Occupational Therapy Utilization in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study.

B. Thombs, C. Mancuso, J. Gordon, 2019, The Journal of rheumatology.